Stockscreener 앱 받기
0.6105
3.65%
0.0215
시간 외 거래:
.62
0.0095
+1.56%
Lexaria Bioscience Corp 주식(LEXX)의 최신 뉴스
Lexaria Bioscience (LEXX) Completes Dosing in Key Animal Study - GuruFocus
Lexaria completes dosing study on next-generation GLP-1 drugs By Investing.com - Investing.com Nigeria
Lexaria completes dosing study on next-generation GLP-1 drugs - Investing.com
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway - Weatherford Democrat
Weight-loss injection retatrutide tested as pill in Lexaria animal trial - Stock Titan
Whoosh Wellness Launches Physician-Guided Telehealth Platform Offering Oral-First Wellness Protocols and Prescribed Microdosing Programs - GlobeNewswire Inc.
Lexaria Bioscience to Attend BIO International Convention as Part of Expanded Business Development Push - citybuzz -
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program - Investing News Network
Lexaria Attending the BIO International Convention, as part of a Broader Business Development Program - TradingView
Lexaria drug platform sees record partner interest ahead of BIO - Stock Titan
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - FinancialContent
Lexaria Bioscience Finds its Niche in the Lucrative GLP-1 Market - The Globe and Mail
Lexaria Bioscience files to sell 2.76M shares of common stock for holders - MSN
Lexaria Gets Attention with GLP-1 Test on Deck - Bez Kabli
LEXX Should I Buy - Intellectia AI
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7 - Investing News Network
MarketsMedicine Hat News - FinancialContent
TradingKey - TradingKey
lxrp_ex991.htm - SEC.gov
Lexaria Bioscience Releases Second Episode of Investor Video Series - Investing News Network
What Lexaria's CEO says is next for GLP-1 research in 2026 - Stock Titan
Lexaria advances semaglutide study with ethics review submission By Investing.com - Investing.com India
Lexaria Updates Progress on Human Study #7 - Investing News Network
Lexaria advances semaglutide study with ethics review submission - Investing.com
Lexaria targets mid-June start for 5-week oral semaglutide study - Stock Titan
Lexaria Bioscience stock soars after ending $5M stock sale agreement with JonesTrading - MSN
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications - Investing News Network
Lexaria’s new video series zeroes in on a $75B GLP-1 market - Stock Titan
Lexaria Extends Material Transfer Agreement with PharmaCO Through 2026 for GLP-1 Drug Delivery Technology Evaluation - MEXC
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Investing News Network
Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Th - GuruFocus
Lexaria Bioscience (LEXX) Extends Collaboration with PharmaCO Through 2026 - GuruFocus
Lexaria extends pharma partnership to evaluate GLP-1 technology By Investing.com - Investing.com South Africa
Lexaria extends pharma partnership to evaluate GLP-1 technology - Investing.com
2.60%
0.94%
자본화:
|
볼륨(24시간):